Table II.
Univariate and multivariate analysis of OS for all patients (n=114).
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variables | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age, years | ||||
| <65 vs. ≥65 | 1.21 (0.68–2.19) | 0.51 | 0.59 (0.31–1.12) | 0.11 |
| PS | ||||
| 0 vs. 1,2 | 3.12 (1.76–5.51) | <0.0001 | 1.53 (0.84–2.79) | 0.16 |
| Stagea | ||||
| 1,2,3,4 | ||||
| 2.46 (1.73–3.50) | <0.0001 | 2.19 (1.41–3.43) | 0.0006 | |
| Residual tumor | ||||
| No vs. yes | 4.30 (2.24–8.25) | <0.0001 | 1.79 (0.77–4.18) | 0.18 |
| SPTb | ||||
| No vs. yes | 0.40 (0.23–0.70) | 0.001 | 0.30 (0.16–0.54) | <0.0001 |
a
Stage is an ordinal variable.
b
SPT was defined as completing at least 6 cycles of adjuvant chemotherapy after surgery in principle. Bold print indicates statistically significant P-values. HR, hazard ratio; 95% CI, 95% confidence interval; PS, performance status; SPT, standard primary therapy.